Review of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial results, and potential to reshape cardiometabolic disease treatment.
Key findingReview of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial re
What the researchers found
Review of survodutide, a dual GLP-1/glucagon agonist, covers its unique mechanism, clinical trial results, and potential to reshape cardiometabolic disease treatment.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.
Cardiology in review
Citation
Arun, Amogh Jyothi; Darji, Bhavika; Baig, Madiha; Frishman, William H; Aronow, Wilbert S. (2025). Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000001062